BIOMARKER:

ALK positive

A1 | Sensitive

A2 | Sensitive

B | Sensitive

C1 | Sensitive

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

D | Sensitive

A1 | Resistant

A2 | Resistant

B | Resistant

C1 | Resistant

C2 | Resistant

C3 | Resistant

C4 | Resistant

D | Resistant

Non Small Cell Lung Cancer

Peripheral T-cell Lymphoma

Non-Hodgkin’s Lymphoma

Lung Non-Squamous Non-Small Cell Cancer

Lung Adenocarcinoma

T Cell Non-Hodgkin Lymphoma

Neuroblastoma

Solid Tumor

Lung Cancer

Lymphoma

Neuroendocrine Tumor

Diffuse Large B Cell Lymphoma

Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia

Lung Non-Small Cell Squamous Cancer

Mesothelioma

crizotinib

ALK positive|Peripheral T-cell Lymphoma|crizotinib

ALK positive|Non Small Cell Lung Cancer|crizotinib

ALK positive|Lung Non-Squamous Non-Small Cell Cancer|crizotinib

ALK positive|Non-Hodgkin’s Lymphoma|crizotinib

ALK positive|T Cell Non-Hodgkin Lymphoma|crizotinib

ALK positive|Neuroblastoma|crizotinib

ALK positive|Lymphoma|crizotinib

lorlatinib

ALK positive|Peripheral T-cell Lymphoma|lorlatinib

ALK positive|Non Small Cell Lung Cancer|lorlatinib

ALK positive|Lung Adenocarcinoma|lorlatinib

ALK positive|Neuroblastoma|lorlatinib

ALK positive|Lung Cancer|lorlatinib

ALK positive|Diffuse Large B Cell Lymphoma|lorlatinib

alectinib

ALK positive|Peripheral T-cell Lymphoma|alectinib

ALK positive|Non Small Cell Lung Cancer|alectinib

ALK positive|Non-Hodgkin’s Lymphoma|alectinib

ALK positive|Neuroendocrine Tumor|alectinib

ceritinib

ALK positive|Peripheral T-cell Lymphoma|ceritinib

ALK positive|Non Small Cell Lung Cancer|ceritinib

ALK positive|Non-Hodgkin’s Lymphoma|ceritinib

ALK positive|Lung Adenocarcinoma|ceritinib

ALK positive|T Cell Non-Hodgkin Lymphoma|ceritinib

brigatinib

ALK positive|Peripheral T-cell Lymphoma|brigatinib

ALK positive|Non Small Cell Lung Cancer|brigatinib

ALK positive|T Cell Non-Hodgkin Lymphoma|brigatinib

ALK positive|Lung Non-Small Cell Squamous Cancer|brigatinib

bevacizumab

ALK positive|Lung Non-Squamous Non-Small Cell Cancer|bevacizumab

APG-2449

ALK positive|Non Small Cell Lung Cancer|APG-2449

ALK positive|Mesothelioma|APG-2449

ensartinib

ALK positive|Non Small Cell Lung Cancer|ensartinib

ALK positive|Lung Non-Squamous Non-Small Cell Cancer|ensartinib

atezolizumab

ALK positive|Non Small Cell Lung Cancer|atezolizumab

ALK positive|Lung Non-Squamous Non-Small Cell Cancer|atezolizumab

brentuximab vedotin

ALK positive|Non-Hodgkin’s Lymphoma|brentuximab vedotin

ALK positive|T Cell Non-Hodgkin Lymphoma|brentuximab vedotin

TQ-B3101

ALK positive|Non-Hodgkin’s Lymphoma|TQ-B3101

ALK positive|Solid Tumor|TQ-B3101

ibrutinib

ALK positive|Small Lymphocytic Lymphoma|ibrutinib

ALK positive|Chronic Lymphocytic Leukemia|ibrutinib

SY-707

ALK positive|Non Small Cell Lung Cancer|SY-707

chidamide

ALK positive|Peripheral T-cell Lymphoma|chidamide

bevacizumab + alectinib

ALK positive|Lung Non-Squamous Non-Small Cell Cancer|bevacizumab + alectinib

SY-3505

ALK positive|Non Small Cell Lung Cancer|SY-3505

TGRX-326

ALK positive|Non Small Cell Lung Cancer|TGRX-326

AUY922

ALK positive|Non Small Cell Lung Cancer|AUY922

sintilimab

ALK positive|Non Small Cell Lung Cancer|sintilimab

repotrectinib

ALK positive|Solid Tumor|repotrectinib

crizotinib + alectinib

ALK positive|Non Small Cell Lung Cancer|crizotinib + alectinib

trametinib + ceritinib

ALK positive|Non Small Cell Lung Cancer|trametinib + ceritinib

pemetrexed

ALK positive|Lung Adenocarcinoma|pemetrexed

entrectinib

ALK positive|Non Small Cell Lung Cancer|entrectinib

TQ-B3139

ALK positive|Non Small Cell Lung Cancer|TQ-B3139

iruplinalkib

ALK positive|Non Small Cell Lung Cancer|iruplinalkib

ruxolitinib

ALK positive|Lung Adenocarcinoma|ruxolitinib

lorlatinib + camrelizumab

ALK positive|Lung Adenocarcinoma|lorlatinib + camrelizumab

bevacizumab + atezolizumab

ALK positive|Non Small Cell Lung Cancer|bevacizumab + atezolizumab

atezolizumab + alectinib

ALK positive|Non Small Cell Lung Cancer|atezolizumab + alectinib

pembrolizumab

ALK positive|Non Small Cell Lung Cancer|pembrolizumab

SAF-189

ALK positive|Non Small Cell Lung Cancer|SAF-189

alectinib + SHP099

ALK positive|Lung Cancer|alectinib + SHP099

CART-30

ALK positive|Non-Hodgkin’s Lymphoma|CART-30

ASTX660

ALK positive|Lymphoma|ASTX660

trametinib + crizotinib

ALK positive|Non-Hodgkin’s Lymphoma|trametinib + crizotinib

ADX-1612

ALK positive|Non Small Cell Lung Cancer|ADX-1612

ADCT-301

ALK positive|Non-Hodgkin’s Lymphoma|ADCT-301

crizotinib + LB-100

ALK positive|Peripheral T-cell Lymphoma|crizotinib + LB-100

CFT7455

ALK positive|T Cell Non-Hodgkin Lymphoma|CFT7455

alectinib + brigatinib

ALK positive|Lung Adenocarcinoma|alectinib + brigatinib

PD-L1 inhibitor

ALK positive|Non Small Cell Lung Cancer|PD-L1 inhibitor

Tyrosine kinase inhibitor

ALK positive|Non Small Cell Lung Cancer|Tyrosine kinase inhibitor

CMOP

ALK positive|Peripheral T-cell Lymphoma|CMOP

CAR-T immunotherapy

ALK positive|Neuroblastoma|CAR-T immunotherapy

ALK inhibitor

ALK positive|Non Small Cell Lung Cancer|ALK inhibitor